Skip to main content
Top
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Lymphoma | Research article

Reliable cell and tissue morphology-based diagnosis of endemic Burkitt lymphoma in resource-constrained settings in Ghana

Authors: Cecilia Smith-Togobo, Mette Ø. Pedersen, Steffen G. Jensen, Babatunde Duduyemi, Richard K. Gyasi, Michael F. Ofori, Vivian Paintsil, Lorna Renner, Peter Nørgaard, Lars Hviid

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

Endemic Burkitt lymphoma (eBL) is an aggressive B-cell lymphoma, which is a common childhood cancer in areas with intense transmission of Plasmodium falciparum parasites. Early and accurate diagnosis is a prerequisite for successful therapy, but it optimally involves advanced laboratory investigations. These are technologically demanding, expensive, and often difficult to implement in settings where eBL is prevalent. Diagnosis is thus generally based on clinical assessment and morphological examination of tumour biopsies or fine-needle aspirates (FNAs).

Methods

The purpose of the present study was to assess the accuracy of eBL diagnosis at two tertiary hospitals in Ghana. To that end, we studied FNAs from 29 eBL patients and 21 non-eBL lymphoma patients originally diagnosed in 2018. In addition, we examined 111 archival formalin-fixed and paraffin-embedded (FFPE) biopsies from Ghanaian patients originally diagnosed as eBL (N = 55) or non-eBL (N = 56) between 2010 and 2017. Availability-based subsets of samples were subjected to haematoxylin-eosin or Giemsa staining, C-MYC immunohistochemistry, and fluorescence in situ hybridisation (FISH) analysis of c-myc rearrangements.

Results

We found a good correlation between original diagnosis and subsequent retrospective assessment, particularly for FNA samples. However, evidence of intact c-myc genes and normal C-MYC expression in samples from some patients originally diagnosed as eBL indicates that morphological assessment alone can lead to eBL over-diagnosis in our study area. In addition, several FFPE samples could not be assessed retrospectively, due to poor sample quality. Therefore, the simpler FNA method of obtaining tumour material is preferable, particularly when careful processing of biopsy specimens cannot be guaranteed.

Conclusion

We conclude that the accuracy of eBL diagnostic tools available in Ghana is generally adequate, but could be improved by implementation of additional pathology laboratory investigations. Improved attention to adequate preservation of archival samples is recommended.
Appendix
Available only for authorised users
Literature
1.
go back to reference Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO classification of tumours of haematopoietic and lymphoid tissues. Geneva: World Health Organization; 2017. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO classification of tumours of haematopoietic and lymphoid tissues. Geneva: World Health Organization; 2017.
2.
go back to reference Burkitt D. A sarcoma involving the jaws in African children. Br J Surg. 1958;46:218–23.CrossRef Burkitt D. A sarcoma involving the jaws in African children. Br J Surg. 1958;46:218–23.CrossRef
3.
go back to reference Burkitt D. A children's cancer dependent on climatic factors. Nature. 1962;194:232–4.CrossRef Burkitt D. A children's cancer dependent on climatic factors. Nature. 1962;194:232–4.CrossRef
4.
go back to reference Quintana M, Smith-Togobo C, Moormann A, Hviid L. Endemic Burkitt lymphoma - an aggressive childhood cancer linked to Plasmodium falciparum exposure, but not to exposure to other malaria parasites. APMIS. (in press). Quintana M, Smith-Togobo C, Moormann A, Hviid L. Endemic Burkitt lymphoma - an aggressive childhood cancer linked to Plasmodium falciparum exposure, but not to exposure to other malaria parasites. APMIS. (in press).
5.
go back to reference Nkrumah FK, Perkins IV. Burkitt’s lymphoma: a clinical study of 110 patients. Cancer. 1976;37:671–6.CrossRef Nkrumah FK, Perkins IV. Burkitt’s lymphoma: a clinical study of 110 patients. Cancer. 1976;37:671–6.CrossRef
6.
go back to reference Segbefia CI, Renner LA, Dei-Adomakoh Y, Welbeck J. Changing patterns of childhood cancers at Korle Bu teaching hospital, Accra, Ghana. Postgrad Med J Ghana. 2013;2:65–7. Segbefia CI, Renner LA, Dei-Adomakoh Y, Welbeck J. Changing patterns of childhood cancers at Korle Bu teaching hospital, Accra, Ghana. Postgrad Med J Ghana. 2013;2:65–7.
7.
go back to reference Diebold J, Jaffe ES, Raphael M, Warnke RA. Burkitt lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues, vol. 3. Edited by. Lyon: IARC Press; 2001. p. 181–4. Diebold J, Jaffe ES, Raphael M, Warnke RA. Burkitt lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues, vol. 3. Edited by. Lyon: IARC Press; 2001. p. 181–4.
8.
go back to reference Aquino G, Marra L, Curcio MP, De Chiara A, Liguori G, Franco R. Detection of myc rearranged by fluorescence in situ hybridization FISH: a diagnostic tool. World Cancer Res J. 2014;1:e362. Aquino G, Marra L, Curcio MP, De Chiara A, Liguori G, Franco R. Detection of myc rearranged by fluorescence in situ hybridization FISH: a diagnostic tool. World Cancer Res J. 2014;1:e362.
11.
go back to reference Pedersen MO, Gang AO, Clasen-Linde E, Breinholt MF, Knudsen H, Nielsen SL, Poulsen TS, Klausen TW, Hogdall E, Norgaard P. Stratification by MYC expression has prognostic impact in MYC translocated B-cell lymphoma - identifies a subgroup of patients with poor outcome. Eur J Haematol. 2019;102:395–406. https://doi.org/10.1111/ejh.13219.CrossRefPubMed Pedersen MO, Gang AO, Clasen-Linde E, Breinholt MF, Knudsen H, Nielsen SL, Poulsen TS, Klausen TW, Hogdall E, Norgaard P. Stratification by MYC expression has prognostic impact in MYC translocated B-cell lymphoma - identifies a subgroup of patients with poor outcome. Eur J Haematol. 2019;102:395–406. https://​doi.​org/​10.​1111/​ejh.​13219.CrossRefPubMed
13.
go back to reference Altman DG, Machin D, Bryant TN, Gardner MJ. Statistics with confidence, 2nd edn. London: British Medical Journal; 2000. Altman DG, Machin D, Bryant TN, Gardner MJ. Statistics with confidence, 2nd edn. London: British Medical Journal; 2000.
14.
go back to reference Wagener R, Bens S, Toprak UH, Seufert J, Lopez C, Scholz I, Herbrueggen H, Oschlies I, Stilgenbauer S, Schlesner M, et al. Cryptic insertion of MYC exons 2 and 3 into the IGH locus detected by whole genome sequencing in a case of MYC-negative Burkitt lymphoma. Haematologica. 2019. https://doi.org/10.3324/haematol.2018.208140. Wagener R, Bens S, Toprak UH, Seufert J, Lopez C, Scholz I, Herbrueggen H, Oschlies I, Stilgenbauer S, Schlesner M, et al. Cryptic insertion of MYC exons 2 and 3 into the IGH locus detected by whole genome sequencing in a case of MYC-negative Burkitt lymphoma. Haematologica. 2019. https://​doi.​org/​10.​3324/​haematol.​2018.​208140.
16.
go back to reference Wennborg AD, Altiok E, Moore JP, Ernberg I, Klein G. Differential c-myc protein expression in Burkitt's lymphomas and EBV-transformed lymphoblastoid lines. Eur J Cancer. 1991;27:1643–5.CrossRef Wennborg AD, Altiok E, Moore JP, Ernberg I, Klein G. Differential c-myc protein expression in Burkitt's lymphomas and EBV-transformed lymphoblastoid lines. Eur J Cancer. 1991;27:1643–5.CrossRef
18.
go back to reference Burkitt DP. The discovery of Burkitt’s lymphoma. Cancer. 1983;51:1777–86.CrossRef Burkitt DP. The discovery of Burkitt’s lymphoma. Cancer. 1983;51:1777–86.CrossRef
Metadata
Title
Reliable cell and tissue morphology-based diagnosis of endemic Burkitt lymphoma in resource-constrained settings in Ghana
Authors
Cecilia Smith-Togobo
Mette Ø. Pedersen
Steffen G. Jensen
Babatunde Duduyemi
Richard K. Gyasi
Michael F. Ofori
Vivian Paintsil
Lorna Renner
Peter Nørgaard
Lars Hviid
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-6488-1

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine